FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1970792361> ?p ?o ?g. }

• W1970792361 endingPage "12060" @default.
• W1970792361 startingPage "12056" @default.
• W1970792361 abstract "The very late antigen (VLA)-4 and VLA-5 integrins mediate hematopoietic progenitor cell attachment to bone marrow (BM) stroma. Transforming growth factor-β1 (TGF-β1) is a cytokine present in the BM microenvironment that has been shown to regulate the synthesis of adhesion elements in several cell types. We have investigated whether TGF-β1 action on human BM stromal cells affected the adhesion of progenitor cells involving integrins VLA-4 and VLA-5. Two precursor cell lines, pre-B Nalm-6 and the multipotential UT-7, attached to untreated primary stroma and to the human BM stromal cell line Str-5 preferentially using VLA-4. However, treatment of the stroma with TGF-β1 resulted in a significant reduction in the participation of VLA-4 in mediating precursor cell adhesion to stroma and a concomitant increase in the utilization of VLA-5. This effect was not exclusive of normal BM stroma. Treatment with TGF-β1 of stroma from multiple myeloma BM samples produced a substantial increase in VLA-5 use by the myeloma cell line NCI-H929 to adhere to this stroma. The differential use of VLA-4 and VLA-5 correlated with an increase in fibronectin surface expression by stromal cells in response to TGF-β1. Adhesion assays to purified fibronectin using Nalm-6 cells showed a predominant utilization of VLA-4 at low concentrations of this ligand, whereas higher concentrations resulted in a preferential use of VLA-5. These results indicate that regulation of fibronectin expression on BM stromal cells by TGF-β1 results in a modulation of the pattern of integrins used by the precursor and myeloma cells to adhere to BM stroma, which could have important consequences on the proliferation and differentiation of hematopoietic precursor cells as well as on the localization and growth of myeloma cells. The very late antigen (VLA)-4 and VLA-5 integrins mediate hematopoietic progenitor cell attachment to bone marrow (BM) stroma. Transforming growth factor-β1 (TGF-β1) is a cytokine present in the BM microenvironment that has been shown to regulate the synthesis of adhesion elements in several cell types. We have investigated whether TGF-β1 action on human BM stromal cells affected the adhesion of progenitor cells involving integrins VLA-4 and VLA-5. Two precursor cell lines, pre-B Nalm-6 and the multipotential UT-7, attached to untreated primary stroma and to the human BM stromal cell line Str-5 preferentially using VLA-4. However, treatment of the stroma with TGF-β1 resulted in a significant reduction in the participation of VLA-4 in mediating precursor cell adhesion to stroma and a concomitant increase in the utilization of VLA-5. This effect was not exclusive of normal BM stroma. Treatment with TGF-β1 of stroma from multiple myeloma BM samples produced a substantial increase in VLA-5 use by the myeloma cell line NCI-H929 to adhere to this stroma. The differential use of VLA-4 and VLA-5 correlated with an increase in fibronectin surface expression by stromal cells in response to TGF-β1. Adhesion assays to purified fibronectin using Nalm-6 cells showed a predominant utilization of VLA-4 at low concentrations of this ligand, whereas higher concentrations resulted in a preferential use of VLA-5. These results indicate that regulation of fibronectin expression on BM stromal cells by TGF-β1 results in a modulation of the pattern of integrins used by the precursor and myeloma cells to adhere to BM stroma, which could have important consequences on the proliferation and differentiation of hematopoietic precursor cells as well as on the localization and growth of myeloma cells. The bone marrow stromal cells (BMSC) 1The abbreviations used are: BMSC, bone marrow stromal cells; BM, bone marrow; VLA, very late antigen; FN, fibronectin; VCAM-1, vascular cell adhesion molecule-1; TGF-β, transforming growth factor-β; IMDM, Iscove's modified Dulbecco's medium; ELISA, enzyme-linked immunosorbent assay; BCECF-AM, 2′,7′-bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester; mAb, monoclonal antibody.1The abbreviations used are: BMSC, bone marrow stromal cells; BM, bone marrow; VLA, very late antigen; FN, fibronectin; VCAM-1, vascular cell adhesion molecule-1; TGF-β, transforming growth factor-β; IMDM, Iscove's modified Dulbecco's medium; ELISA, enzyme-linked immunosorbent assay; BCECF-AM, 2′,7′-bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester; mAb, monoclonal antibody. constitute a population of different cell types that provide the bone marrow (BM) microenvironment with a wealth of cytokines necessary for sustained hematopoiesis and that express membrane ligands for adhesion receptors on hematopoietic progenitor cells (1Dorshkind K. Annu. Rev. Immunol. 1990; 8: 111-137Crossref PubMed Scopus (445) Google Scholar). The integrins VLA-4 and VLA-5 are among the main adhesion receptors used by CD34high, precursor, and leukemic cells to attach to stroma, interacting with different regions on fibronectin (FN), whereas VLA-4 can additionally bind to VCAM-1, which is constitutively expressed by BMSC (2Teixidó J. Hemler M.E. Greenberger J.S. Anklesaria P. J. Clin. Invest. 1992; 90: 358-367Crossref PubMed Scopus (338) Google Scholar, 3Ryan D.H. Nuccie B.L. Abboud C.N. Winslow J.M. J. Clin. Invest. 1991; 88: 995-1004Crossref PubMed Scopus (185) Google Scholar, 4Uchiyama H. Barut A.B. Chauhan D. Cannistra S.A. Anderson K.C. Blood. 1992; 80: 2306-2314Crossref PubMed Google Scholar, 5Liesveld J.L. Winslow J.M. Frediani K.E. Ryan D.H. Abboud C.N. Blood. 1993; 81: 112-121Crossref PubMed Google Scholar). TGF-β is a multifunctional cytokine present in the BM microenvironment that is mainly produced by megakaryocytes and by BMSC (6Fava R.A. Casey T.T. Wilcox J. Pelton R.W. Moses H.L. Nanney L.B. Blood. 1990; 76: 1946-1955Crossref PubMed Google Scholar, 7Gimble J.M. Pietrangeli C. Henley A. Dorheim M.A. Silver J. Namen A. Takeichi M. Goridis C. Kincade P.W. Blood. 1989; 74: 303-311Crossref PubMed Google Scholar) and that regulates stem cell proliferation and B lymphopoiesis (8Keller J.R. McNiece I.K. Sill K.T. Ellingsworth L.R. Quesenberry P.J. Sing G.K. Ruscetti F.W. Blood. 1990; 75: 596-602Crossref PubMed Google Scholar, 9Dubois C.M. Ruscetti F.W. Stankova J. Keller J.R. Blood. 1994; 83: 3138-3145Crossref PubMed Google Scholar, 10Lee G. Ellingsworth L.R. Gillis S. Wall R. Kincade P.W. J. Exp. Med. 1987; 166: 1290-1299Crossref PubMed Scopus (105) Google Scholar). The levels of TGF-β have been found to be higher in several leukemias, such as multiple myeloma and B cell chronic lymphocytic leukemia, compared with normal bone marrow (11Urashima M. Ogata A. Chuhan D. Hatziyanni M. Vidriales M.B. Dedera D.A. Schlossman R.L. Anderson K.C. Blood. 1996; 87: 1928-1938Crossref PubMed Google Scholar, 12Lagneaux L. Delforge A. Dorval C. Bron D. Stryckmans P. Blood. 1993; 82: 2379-2385Crossref PubMed Google Scholar). We have recently characterized the TGF-β1 receptor system on primary human BMSC, showing the expression of the serine/threonine kinase transducing type I and II receptors as well as endoglin (13Robledo M.M. Hidalgo A. Lastres P. Arroyo A.G. Bernabeu C. Sánchez-Madrid F. Teixidó J. Br. J. Haematol. 1996; 93: 507-514Crossref PubMed Scopus (47) Google Scholar). Little is known about the effects of TGF-β on stromal cell function. Potential targets for its action include the control of cell proliferation and the regulation of the synthesis of adhesion elements, such as extracellular matrix proteins, and extracellular matrix protein-degrading proteases (14Massagué J. Annu. Rev. Cell Biol. 1990; 6: 597-641Crossref PubMed Scopus (2990) Google Scholar). Changes in the expression of adhesion elements on BMSC at different niches or during different stages of differentiation could result in variations in the adhesion of maturing precursor cells and could also influence the localization of tumor cells in the BM. In this work, we have studied the involvement of integrins VLA-4 and VLA-5 in progenitor cell adhesion to TGF-β1-treated stroma. Normal BM was obtained after informed consent from donors for allogeneic bone marrow transplants. Multiple myeloma BM samples were obtained from untreated patients with active disease. The stromal cultures were generated as described previously (13Robledo M.M. Hidalgo A. Lastres P. Arroyo A.G. Bernabeu C. Sánchez-Madrid F. Teixidó J. Br. J. Haematol. 1996; 93: 507-514Crossref PubMed Scopus (47) Google Scholar) and maintained in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal calf serum (complete medium) and 10−5m hydrocortisone sodium succinate. Non-adherent cells were removed after 1 week, and upon confluency, the stromal cells were passaged by trypsin/EDTA. After four passages, they were seeded 1 week before use in 96-well plates for adhesion and cell ELISAs. Our BM stromal monolayers consisted mainly of fibroblasts and macrophages, with a low percentage of endothelial cells (13Robledo M.M. Hidalgo A. Lastres P. Arroyo A.G. Bernabeu C. Sánchez-Madrid F. Teixidó J. Br. J. Haematol. 1996; 93: 507-514Crossref PubMed Scopus (47) Google Scholar). The human bone marrow stromal cell line Str-5 was maintained in complete medium (13Robledo M.M. Hidalgo A. Lastres P. Arroyo A.G. Bernabeu C. Sánchez-Madrid F. Teixidó J. Br. J. Haematol. 1996; 93: 507-514Crossref PubMed Scopus (47) Google Scholar). For TGF-β1 treatments, stromal cultures were first incubated in IMDM supplemented with 1% fetal calf serum and serum replacement medium (2× TCM, ICN Biomedicals) for 24 h, followed by a 24-h incubation in the same medium in the presence of recombinant human TGF-β1 (R&D Systems, Abingdon, United Kingdom), and this medium was removed by aspiration before assays. The pre-B Nalm-6, myeloma NCI-H929, and Burkitt lymphoma Ramos cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (and 50 μm2-mercaptoethanol for the NCI-H929 cells). The multipotential cell line UT-7 (15Komatsu N. Nakauchi H. Miwa A. Ishihara T. Eguchi M. Moroi M. Okada M. Sato Y. Wada H. Yawata Y. Suda T. Miura Y. Cancer Res. 1991; 51: 341-348PubMed Google Scholar), which expresses CD34 and CD33, was grown in α-minimum Eagle's medium in the presence of 10% fetal calf serum and 2 ng/ml granulocyte-macrophage colony-stimulating factor. Antibodies used in this study included monoclonal P3X63 (16Lemke H. Hammerling G.J. Hofmann C. Rajewsky K. Nature. 1978; 271: 249-251Crossref PubMed Scopus (115) Google Scholar), anti-α4 HP1/2 (17Sánchez-Madrid F. de Landázuri M.O. Morago G. Cebrián M. Acevedo A. Bernabeu C. Eur. J. Immunol. 1986; 16: 1342-1349Crossref Scopus (156) Google Scholar), anti-α5 SAM-1 (18te Velde A.A. Klomp J.P. Yard B.A. de Vries J.E. Figdor C.G. J. Immunol. 1988; 140: 1548-1554PubMed Google Scholar), and P1D6 (Life Technologies, Inc.), Bear-1 anti-CD11b (18te Velde A.A. Klomp J.P. Yard B.A. de Vries J.E. Figdor C.G. J. Immunol. 1988; 140: 1548-1554PubMed Google Scholar), anti-VCAM-1 4B9 (19Schwartz B.R. Wayner E.A. Carlos T.M. Ochs H.D. Harlan J.M. J. Clin. Invest. 1990; 85: 2019-2022Crossref PubMed Scopus (123) Google Scholar), and polyclonal anti-FN central cell-binding domain Rb110 and anti-FN carboxyl-terminal CS-1-containing cell-binding domain Rb113. TGF-β levels from stromal supernatants were determined in a bioassay by analyzing the growth inhibition of mink lung epithelial Mv1Lu cells (American Type Culture Collection CCL 64). Mv1Lu cells were subcultured in IMDM supplemented with 10% fetal calf serum in 24-well tissue culture plates at 3 × 104 cells/well. TGF-β1 (0.1–10 ng/ml) or 24-h stromal supernatants in IMDM supplemented with 1% fetal calf serum and 2× TCM were added without previous acidification to Mv1Lu cells in triplicates, which were incubated for 24 h at 37 °C, the last 4 h in the presence of 1 μCi/well [3H]thymidine (Amersham International, Buckinghamshire, UK). At the end of incubation, cells were washed with phosphate-buffered saline and extracted with 0.2 n NaOH, and extracts were neutralized with 1 m HCl before adding scintillation liquid and analyzed in a β-counter. Cell lines were labeled in their respective growth medium with the fluorescent dye BCECF-AM (Molecular Probes, Leiden, The Netherlands) and finally resuspended in RPMI 1640 medium containing 0.4% bovine serum albumin (adhesion medium). For cell adhesion to purified plasma fibronectin (Sigma), increasing concentrations of this ligand were coated overnight at 4 °C in 100 mm NaHCO3 (pH 8.8), followed by 2-h incubation at 37 °C and then blocking with 0.4% bovine serum albumin in the same solution for 2 h at 37 °C. Preincubations with antibodies were carried out at 37 °C for 15 min, and the antibodies were removed before adhesion. To untreated or TGF-β1-treated stroma or fibronectin in 96-well dishes (Falcon) was added 50 μl of adhesion medium 20 min before adhesion, and after removing it, labeled cells (5 × 104 cells/well) were incubated with the stroma or with fibronectin for 20 min at 37 °C. Unbound cells were removed by three washes with RPMI 1640 medium, and adherent cells were quantified using a fluorescence analyzer (CytoFluor 2300, Millipore Corp.). Untreated or TGF-β1-treated stromal monolayers were fixed with 3.7% formaldehyde in phosphate-buffered saline, washed three times with Tris-buffered saline, and blocked with 3% bovine serum albumin in Tris-buffered saline. After removing the blocking solution, cells were incubated for 1 h at 22 °C with the primary antibodies, washed with Tris-buffered saline in the presence of 0.05% Tween 20, and further incubated for 1 h at 22 °C with peroxidase-conjugated goat anti-rabbit Ig (Dako, Glostrup, Denmark). Monolayers were finally washed and incubated with ABTS (Boehringer Mannheim) in the dark before measuring in an ELISA reader (Multiskan Bichromatic, Labsystems, Helsinki, Finland) at 405 nm. Preparation of the stromal cells for flow cytometry analysis was performed as described previously (13Robledo M.M. Hidalgo A. Lastres P. Arroyo A.G. Bernabeu C. Sánchez-Madrid F. Teixidó J. Br. J. Haematol. 1996; 93: 507-514Crossref PubMed Scopus (47) Google Scholar). Approximately 105 stromal cells were incubated with saturating concentrations of primary antibodies at 4 °C for 45 min. After washing, fluorescein isothiocyanate-conjugated rabbit anti-mouse Ig (Dako) was added and further incubated at 4 °C for 30 min. Samples were analyzed using a Coulter Epics XL flow cytometer. To investigate whether TGF-β1 action on BMSC could influence hematopoietic precursor and myeloma cell adhesion mediated by integrins VLA-4 and VLA-5, we first measured the levels of bioactive TGF-β present in primary human BMSC (HBM-Str) cultures, in the stromal cell line Str-5, and in multiple myeloma BMSC (MM-Str) cultures. Bioassays for TGF-β activity using the TGF-β responder cell line Mv1Lu showed TGF-β-dependent activity corresponding to 0.3–0.6 ng/ml in HBM-Str cells cultured for 24 h, whereas Str-5 and MM-Str cells secreted bioactive TGF-β in the range of 2–2.5 ng/ml (Fig. 1). Incubation of primary stroma with 1 ng/ml TGF-β1 resulted in a decrease in the adhesion of the pre-B cell line Nalm-6 compared with the adhesion to untreated stroma (Fig.2 A). The anti-α4 HP1/2 mAb significantly inhibited (30–40%; p < 0.05) the adhesion of Nalm-6 cells to untreated stroma, but inhibition by HP1/2 was consistently decreased when the adhesion was performed on TGF-β1-incubated stroma. In contrast, the anti-α5 SAM-1 mAb minimally inhibited Nalm-6 cell adhesion to untreated stroma; however, incubation of stroma with TGF-β1 resulted in a blockade of cell adhesion by SAM-1, as well as by another anti-α5 mAb called P1D6 (data not shown), of ∼50% (p < 0.05) (Fig.2 A). The results of inhibition of Nalm-6 cell adhesion using a mixture of anti-α4 and anti-α5 mAbs mimicked those of inhibition with single mAbs. Thus, HP1/2 and SAM-1 together inhibited slightly better than HP1/2 alone the adhesion of Nalm-6 cells to untreated stroma (Fig. 2 A), reflecting a major VLA-4 use. After incubation of the stroma with TGF-β1, the combination of both antibodies inhibited similarly to SAM-1 alone, indicating a predominant VLA-5 utilization. The anti-VCAM-1 4B9 mAb inhibited by 15–20% the adhesion of Nalm-6 cells to either untreated or TGF-β1-treated stroma (Fig. 2 A). The effect of TGF-β1 action on Nalm-6 cell adhesion to HBM-Str was also evident when we preincubated the Str-5 cells with increasing concentrations of TGF-β1, although in this case, higher concentrations of the cytokine were needed to obtain a substantial blocking of Nalm-6 cell adhesion by the anti-α5 mAb (Fig.2 B). In parallel experiments, the SAM-1 and P1D6 mAbs did not inhibit the adhesion of the VLA-5-negative B cell line Ramos either to untreated or TGF-β1-treated HBM-Str cells (data not shown). As for the case of Nalm-6 cells, preincubation of HBM-Str cells with TGF-β1 resulted in a decrease in the adhesion of the multipotential cell line UT-7 (Fig. 2 C). Interestingly, both HP1/2 and, to a lesser extent, SAM-1 inhibited the adhesion of UT-7 cells to untreated stroma. However, TGF-β1 treatment of the stroma resulted in a notable reduction in HP1/2 inhibition of cell adhesion, whereas inhibition by SAM-1 remained unchanged, indicating a predominant VLA-5 use. We could not observe any clear effect of the anti-VCAM-1 mAb on UT-7 cell adhesion to stroma, suggesting that VLA-4 on these cells mainly interacts with fibronectin. To study if the differential use of VLA-4 and VLA-5 could also be observed using leukemic BM stroma, we generated stromal cell cultures from multiple myeloma BM samples and analyzed the effect of their incubation with TGF-β1 on the adhesion of the myeloma-derived cell line NCI-H929. These monolayers expressed abundant fibronectin and substantial levels of VCAM-1 (data not shown). 2M. M. Robledo, F. Sanz-Rodriguez, A. Hidalgo, and J. Teixidó, manuscript in preparation. Similarly to Nalm-6 and UT-7 cells, NCI-H929 cells adhered significantly less to TGF-β1-treated compared with untreated multiple myeloma stroma (Fig.3). The anti-α4 HP1/2 mAb inhibited NCI-H929 cell adhesion to untreated stroma by ∼40% (p < 0.05) and to a lower extent after treatment with TGF-β1. As observed for Nalm-6 cells, a low degree of inhibition of NCI-H929 cell adhesion to untreated stroma was detected with the anti-α5 mAb P1D6, but after TGF-β1 incubation of the multiple myeloma stroma, a high induction of blocking by this antibody was obtained (Fig. 3). The anti-VCAM-1 4B9 mAb inhibited normally 15–25% of NCI-H929 cell adhesion to both untreated and TGF-β1-treated multiple myeloma stroma. One of the targets of TGF-β action is the control of extracellular matrix protein synthesis (14Massagué J. Annu. Rev. Cell Biol. 1990; 6: 597-641Crossref PubMed Scopus (2990) Google Scholar, 20Ignotz R.A. Massagué J. J. Biol. Chem. 1986; 261: 4337-4345Abstract Full Text PDF PubMed Google Scholar). As fibronectin is expressed by stromal cells and is a ligand for both VLA-4 and VLA-5, we analyzed whether FN levels on the surface of stromal cells were affected by TGF-β1. Cellular ELISAs consistently showed an augmentation in FN deposition by HBM-Str cells in response to TGF-β1, as measured by antibodies against the FN central cell-binding domain and the CS-1-containing region (Fig. 4). These results were confirmed by [35S]Met/Cys metabolic labeling of stroma, where a 2.5-fold increase in gelatin-bound extracellular FN was observed upon TGF-β1 treatment (Fig. 4). When the expression of VCAM-1 on stromal cells was analyzed by flow cytometry, a significant reduction was obtained in response to TGF-β1 (data not shown), similar to previous results (21Dittel B.N. McCarthy J.B. Wayner E.A. Le Bien T.W. Blood. 1993; 81: 2272-2282Crossref PubMed Google Scholar). The same experiments showed no effect of TGF-β1 on VLA-β1 or CD11b expression on these cells. To investigate possible mechanisms underlying the potential preferential receptor usage, we carried out cell adhesion assays with increasing concentrations of human plasma fibronectin using Nalm-6 cells. The cells adhered to fibronectin in a concentration-dependent manner in the presence of control P3 antibodies, reaching saturation at ∼30 μg/ml (Fig.5). The inhibition of Nalm-6 cell adhesion to fibronectin by anti-α4 and anti-α5 antibodies displayed three different patterns, depending on the concentrations of fibronectin used. At the lowest concentrations of FN (2–4 μg/ml), the anti-α4 HP1/2 mAb notably inhibited Nalm-6 cell adhesion, whereas the anti-α5 P1D6 mAb did not block, suggesting a predominant VLA-4 use (Fig. 5). When the concentration of FN was increased (8–12 μg/ml), HP1/2 showed no or modest inhibition of Nalm-6 cell adhesion, whereas P1D6 significantly inhibited this adhesion, indicating a preferential VLA-5 utilization. At the highest concentrations of fibronectin (>16 μg/ml), both P1D6 and HP1/2 inhibited Nalm-6 cell adhesion, although the former inhibited always to a higher extent (Fig.5). In the same experiments, a mixture of antibodies against the FN central cell-binding domain and the CS-1-containing region fully inhibited Nalm-6 cell adhesion when they were preincubated with the fibronectin-coated wells (data not shown), demonstrating the specificity of the adhesion. This study describes novel modulatory roles for TGF-β1 in the adhesion of hematopoietic precursor and myeloma cells to BM stroma. The important finding is that TGF-β1 action on human BMSC resulted in a significant reduction in the participation of VLA-4 in mediating precursor and myeloma cell adhesion to the stroma, linked to an increase in VLA-5 involvement in such adhesion. As shown in TableI, the ratio of VLA-5 versusVLA-4 utilization by Nalm-6 and UT-7 cells increased 10-fold after treatment of the stroma with TGF-β1, whereas this ratio was close to 5-fold in the case of NCI-H929 cells, as determined from values of inhibition of cell adhesion. The results were obtained using TGF-β1 concentrations similar to those found in the supernatants from normal and multiple myeloma stromata, although in UT-7 cells, slightly higher amounts of TGF-β1 were required. We detected lower levels of TGF-β in multiple myeloma stromal cultures compared with a previous report (11Urashima M. Ogata A. Chuhan D. Hatziyanni M. Vidriales M.B. Dedera D.A. Schlossman R.L. Anderson K.C. Blood. 1996; 87: 1928-1938Crossref PubMed Google Scholar), which could be due to the different methods of measurement, as we analyzed bioactive TGF-β, whereas the other study used an ELISA. The differential effects on VLA-4- and VLA-5-mediated cell adhesion are likely at the attachment and possibly spreading levels, as we performed short adhesion assays (20 min), and thus, little, if any, cell migration took place in our system. In addition, it has been reported that most of VLA-4-mediated B cell precursor adhesion to stroma occurs in the first 15 min of cell attachment (22Patrick C.W. Juneja H.S. Lee S. Schmalstieg F.C. McIntire L.W. Blood. 1995; 85: 168-178Crossref PubMed Google Scholar), and therefore, our results were obtained under conditions favoring VLA-4 activity. The modulation of VLA-4 and VLA-5 use by TGF-β1 treatment of stroma takes place in the absence of any exogenously added TGF-β1 in the precursor cell lines, and thus, it is independent of a possible increase in VLA-5 expression due to this cytokine, as has been reported for several cell types (23Heino J. Ignotz R.A. Hemler M.E. Crouse C. Massagué J. J. Biol. Chem. 1989; 264: 380-388Abstract Full Text PDF PubMed Google Scholar, 24Bauvois B. Rouillard D. Sanceau J. Wietzerbin J. J. Immunol. 1992; 148: 3912-3919PubMed Google Scholar).Table IEffect of treatment of BM stroma with TGF-β1 on the differential use of VLA-4 and VLA-5 by Nalm-6, UT-7, and NCI-H929 cellsCell lineα5/α4 ratio inhibition−/+TGF-β1 ratio−TGF-β1+TGF-β1Nalm-60.141.4010UT-70.525.2510NCI-H9290.462.164.7 Open table in a new tab Associated with the decreased implication of VLA-4 in mediating precursor and myeloma cell adhesion to TGF-β1-treated stroma, there was a reduction in adhesion to stroma. A diminished B cell precursor cell adhesion to stroma preincubated with TGF-β1 was also previously reported, which was linked to a reduced expression of VCAM-1 (21Dittel B.N. McCarthy J.B. Wayner E.A. Le Bien T.W. Blood. 1993; 81: 2272-2282Crossref PubMed Google Scholar). In the present work, we observed a moderate participation of the VLA-4/VCAM-1 adhesion pathway in Nalm-6 and NCI-H929 cells, as detected by antibody inhibition of the adhesion, but this interaction was not reduced upon stroma treatment with TGF-β1, suggesting that other adhesion pathways might be affected. This suggests that most of the VLA-4-dependent precursor and myeloma cell adhesion to untreated stroma that we observed takes place by attachment to fibronectin. The data also indicate that the increase in VLA-5 involvement in cell adhesion to TGF-β1-treated stroma does not restore the reduced adhesion. The binding of TGF-β1 to the stroma resulted in an increase in the levels of fibronectin expressed on the surface of stromal cells. Although both the CS-1 and central cell-binding domains of FN were augmented by TGF-β1, the precursor and myeloma cells used predominantly VLA-5 to interact with FN on TGF-β1-treated stroma. To gain some insight into the mechanisms leading to the preferential use of VLA-5 after increased fibronectin deposition on BMSC by TGF-β1, we tested whether changes in the concentration of purified fibronectin could influence the integrins utilized to mediate cell adhesion. The results obtained in the lower and likely more physiological range of FN concentrations mimicked those from adhesion to TGF-β1-treated stroma. Thus, VLA-4 was the predominant receptor used at the lowest concentrations of FN inside this range, whereas VLA-5 was the preferential integrin utilized when the concentration of FN was increased. At high concentrations of fibronectin, VLA-5 use was still higher than VLA-4 use, although the latter retained considerable participation in adhesion to fibronectin. These results suggest that the concentrations of fibronectin modulate the receptor used to mediate cell adhesion, and therefore, TGF-β1 regulation of the expression levels of fibronectin on BMSC finely tunes the pattern of the integrins that will be used by the precursor and myeloma cells to interact with the stroma. The α4 integrins are required for normal development of both B and T precursor cells in bone marrow (25Arroyo A.G. Yang J.T. Rayburn H. Hynes R.O. Cell. 1996; 85: 997-1008Abstract Full Text Full Text PDF PubMed Scopus (288) Google Scholar), and long-term BM cultures have demonstrated the involvement of VLA-4 in lymphopoiesis (26Miyake K. Weissman I.L. Greenberger J.S. Kincade P.W. J. Exp. Med. 1991; 173: 599-607Crossref PubMed Scopus (538) Google Scholar), evidencing the importance of VLA-4-mediated adhesion during hematopoiesis. It is well established that VLA-4 and VLA-5 on stem and precursor cells as well as on several leukemic cells mediate attachment to their ligands on BMSC (2Teixidó J. Hemler M.E. Greenberger J.S. Anklesaria P. J. Clin. Invest. 1992; 90: 358-367Crossref PubMed Scopus (338) Google Scholar, 3Ryan D.H. Nuccie B.L. Abboud C.N. Winslow J.M. J. Clin. Invest. 1991; 88: 995-1004Crossref PubMed Scopus (185) Google Scholar, 4Uchiyama H. Barut A.B. Chauhan D. Cannistra S.A. Anderson K.C. Blood. 1992; 80: 2306-2314Crossref PubMed Google Scholar, 5Liesveld J.L. Winslow J.M. Frediani K.E. Ryan D.H. Abboud C.N. Blood. 1993; 81: 112-121Crossref PubMed Google Scholar). This interaction is important for the differentiation and proliferation of hematopoietic progenitor cells. For instance, VLA-4/FN interaction is required for terminal maturation of Ig-secreting BM cells (27Roldan E. Garcia-Pardo A. Brieva J.A. J. Exp. Med. 1992; 175: 1739-1747Crossref PubMed Scopus (115) Google Scholar). In addition, VLA-4- and VLA-5-mediated cell adhesion to FN decreases the proliferation of both normal hematopoietic and chronic myelogenous leukemia progenitors (28Hurley R.W. McCarthy J.B. Verfaillie C. J. Clin. Invest. 1995; 96: 511-519Crossref PubMed Scopus (188) Google Scholar, 29Lundell B.I. McCarthy J.B. Kovach N.L. Verfaillie C. Blood. 1996; 87: 2450-2458Crossref PubMed Google Scholar), and it has been reported that VLA-5/FN interaction induces apoptosis of hematopoietic progenitor cells (30Sugahara H. Kanakura Y. Furitsu T. Ishihara K. Oritani K. Ikeda H. Kitayama H. Ishikawa J. Hashimoto K. Kanayama Y. Matsuzawa Y. J. Exp. Med. 1994; 179: 1757-1766Crossref PubMed Scopus (98) Google Scholar). TGF-β is present in the BM microenvironment, and it is conceivable that changing amounts of this cytokine in different niches of BM could influence the regulation of hematopoiesis. BMSC secrete TGF-β1 and have the TGF-β1 receptor system necessary for signaling by this cytokine (13Robledo M.M. Hidalgo A. Lastres P. Arroyo A.G. Bernabeu C. Sánchez-Madrid F. Teixidó J. Br. J. Haematol. 1996; 93: 507-514Crossref PubMed Scopus (47) Google Scholar). The differential use of VLA-4 and VLA-5 by progenitor and myeloma cells to adhere to stroma after binding of TGF-β1 to their receptors on the stromal cells suggests a mechanism by which changing adhesive interactions might lead to a modulation of hematopoietic progenitor cell proliferation and differentiation. Additionally, the differential contribution of VLA-4 and VLA-5 to the mediation of myeloma cell attachment to multiple myeloma stroma could influence the localization and proliferation of the malignant plasma cells in bone marrow. We thank Drs. Angeles Garcı́a-Pardo and Francisco Sánchez-Madrid for critical reading of the manuscript and for providing antibodies. We also thank Dr. Carl G. Figdor for SAM-1 and Dr. John M. Harlan for the 4B9 mAb. We are grateful to the Blood Bank Services of Hospital de la Princesa and Hospital 12 de Octubre (Madrid) for bone marrow samples." @default.
• W1970792361 created "2016-06-24" @default.
• W1970792361 creator A5006512969 @default.
• W1970792361 creator A5076275584 @default.
• W1970792361 creator A5083555639 @default.
• W1970792361 creator A5085568242 @default.
• W1970792361 date "1998-05-01" @default.
• W1970792361 modified "2023-10-18" @default.
• W1970792361 title "Differential Use of Very Late Antigen-4 and -5 Integrins by Hematopoietic Precursors and Myeloma Cells to Adhere to Transforming Growth Factor-β1-treated Bone Marrow Stroma" @default.
• W1970792361 cites W1487570186 @default.
• W1970792361 cites W1505978562 @default.
• W1970792361 cites W1507429946 @default.
• W1970792361 cites W1509886380 @default.
• W1970792361 cites W1545476994 @default.
• W1970792361 cites W1575606714 @default.
• W1970792361 cites W1606990197 @default.
• W1970792361 cites W1949097444 @default.
• W1970792361 cites W1981026371 @default.
• W1970792361 cites W1998401620 @default.
• W1970792361 cites W19985982 @default.
• W1970792361 cites W2007245529 @default.
• W1970792361 cites W2011723257 @default.
• W1970792361 cites W2020608323 @default.
• W1970792361 cites W2023487115 @default.
• W1970792361 cites W2045837785 @default.
• W1970792361 cites W2067190714 @default.
• W1970792361 cites W2093835397 @default.
• W1970792361 cites W2118267493 @default.
• W1970792361 cites W2131183827 @default.
• W1970792361 cites W2136819827 @default.
• W1970792361 cites W2150595969 @default.
• W1970792361 cites W2167676805 @default.
• W1970792361 cites W2177231732 @default.
• W1970792361 cites W2273834076 @default.
• W1970792361 cites W2277123120 @default.
• W1970792361 cites W2280573406 @default.
• W1970792361 cites W2409488500 @default.
• W1970792361 cites W315922340 @default.
• W1970792361 doi "https://doi.org/10.1074/jbc.273.20.12056" @default.
• W1970792361 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9575147" @default.
• W1970792361 hasPublicationYear "1998" @default.
• W1970792361 type Work @default.
• W1970792361 sameAs 1970792361 @default.
• W1970792361 citedByCount "33" @default.
• W1970792361 countsByYear W19707923612013 @default.
• W1970792361 countsByYear W19707923612014 @default.
• W1970792361 crossrefType "journal-article" @default.
• W1970792361 hasAuthorship W1970792361A5006512969 @default.
• W1970792361 hasAuthorship W1970792361A5076275584 @default.
• W1970792361 hasAuthorship W1970792361A5083555639 @default.
• W1970792361 hasAuthorship W1970792361A5085568242 @default.
• W1970792361 hasBestOaLocation W19707923611 @default.
• W1970792361 hasConcept C109159458 @default.
• W1970792361 hasConcept C118131993 @default.
• W1970792361 hasConcept C126322002 @default.
• W1970792361 hasConcept C142724271 @default.
• W1970792361 hasConcept C147483822 @default.
• W1970792361 hasConcept C16930146 @default.
• W1970792361 hasConcept C170493617 @default.
• W1970792361 hasConcept C195687474 @default.
• W1970792361 hasConcept C203014093 @default.
• W1970792361 hasConcept C204232928 @default.
• W1970792361 hasConcept C2775960820 @default.
• W1970792361 hasConcept C2776364478 @default.
• W1970792361 hasConcept C2780007613 @default.
• W1970792361 hasConcept C28328180 @default.
• W1970792361 hasConcept C502942594 @default.
• W1970792361 hasConcept C52124034 @default.
• W1970792361 hasConcept C71924100 @default.
• W1970792361 hasConcept C86803240 @default.
• W1970792361 hasConcept C95444343 @default.
• W1970792361 hasConceptScore W1970792361C109159458 @default.
• W1970792361 hasConceptScore W1970792361C118131993 @default.
• W1970792361 hasConceptScore W1970792361C126322002 @default.
• W1970792361 hasConceptScore W1970792361C142724271 @default.
• W1970792361 hasConceptScore W1970792361C147483822 @default.
• W1970792361 hasConceptScore W1970792361C16930146 @default.
• W1970792361 hasConceptScore W1970792361C170493617 @default.
• W1970792361 hasConceptScore W1970792361C195687474 @default.
• W1970792361 hasConceptScore W1970792361C203014093 @default.
• W1970792361 hasConceptScore W1970792361C204232928 @default.
• W1970792361 hasConceptScore W1970792361C2775960820 @default.
• W1970792361 hasConceptScore W1970792361C2776364478 @default.
• W1970792361 hasConceptScore W1970792361C2780007613 @default.
• W1970792361 hasConceptScore W1970792361C28328180 @default.
• W1970792361 hasConceptScore W1970792361C502942594 @default.
• W1970792361 hasConceptScore W1970792361C52124034 @default.
• W1970792361 hasConceptScore W1970792361C71924100 @default.
• W1970792361 hasConceptScore W1970792361C86803240 @default.
• W1970792361 hasConceptScore W1970792361C95444343 @default.
• W1970792361 hasIssue "20" @default.
• W1970792361 hasLocation W19707923611 @default.
• W1970792361 hasLocation W19707923612 @default.
• W1970792361 hasOpenAccess W1970792361 @default.
• W1970792361 hasPrimaryLocation W19707923611 @default.
• W1970792361 hasRelatedWork W1536051969 @default.
• W1970792361 hasRelatedWork W1996764438 @default.
• W1970792361 hasRelatedWork W2015599978 @default.

• next